The Sackler Family Net Worth
The Sackler family net worth is estimated at around $10.8 billion, according to the latest Forbes real-time billionaires list. The fortune is spread across three main branches descended from Arthur, Mortimer, and Raymond Sackler, who built a diversified business empire in pharmaceuticals, real estate, and the arts. The family's wealth remains tightly held through private trusts and holding companies, making precise valuation difficult. The core of the fortune still traces back to the sale and growth of Purdue Pharma, the maker of OxyContin, which generated billions in revenue before its bankruptcy filing in 2019. Despite massive legal settlements, the Sacklers continue to be ranked among the wealthiest families in the United States.
Forbes lists several Sackler family members among the world's billionaires, with the combined family fortune hovering near the top of the global rich list. The wealth is largely concentrated in the hands of descendants of Mortimer and Raymond Sackler, who control major art institutions and private investment vehicles. Arthur Sackler's branch, which pioneered direct-to-physician pharmaceutical marketing, also holds significant assets. The family's net worth has been resilient because much of it was moved into trusts, art collections, and offshore structures long before the opioid crisis unfolded. Public records show that the Sacklers have used complex corporate structures to shield assets from creditors and litigation.
Sources of the Sackler Fortune
Purdue Pharma, founded by the Sacklers in 1952, was the primary engine of the family's wealth for decades. The company's aggressive marketing of OxyContin, a powerful opioid painkiller, generated billions in sales and made the Sacklers one of the richest families in America. Internal documents and court filings reveal that Purdue knew about the addiction risks of OxyContin yet continued to promote it for widespread use. The company's revenue peaked in the early 2000s, driven by prescriptions for chronic pain and aggressive sales tactics targeting doctors. Purdue Pharma filed for Chapter 11 bankruptcy in 2019 as thousands of lawsuits over the opioid epidemic piled up.
Beyond Purdue, the Sacklers built a diversified portfolio through Mundipharma, a global pharmaceutical company they founded and still control. Mundipharma operates independently from Purdue and focuses on pain management and specialty medicines in markets across Asia, Europe, and Latin America. The family also owns significant real estate holdings, including luxury properties in New York, London, and the Hamptons. Major art institutions such as the Sackler Wing at the Metropolitan Museum of Art and the Serpentine Galleries bear the family name, funded by private donations from the Sackler fortune. The Sackler family's business interests also extend into private equity and venture capital through entities like the Sackler Trust.
Legal Settlements and the Opioid Crisis
The Sackler family has faced thousands of lawsuits from states, cities, and individuals blaming Purdue Pharma for fueling the opioid epidemic. In 2021, a federal bankruptcy court approved a settlement that would provide up to $6 billion to settle claims against Purdue, with the Sackler family contributing personal funds and agreeing to give up control of the company. However, the U.S. Supreme Court blocked the deal in 2023, ruling that the bankruptcy plan improperly protected the Sacklers from future civil lawsuits. The court's decision left the Sacklers exposed to additional litigation and increased pressure to reach a new settlement. The legal battles continue to unfold in courts across the country, with new cases and appeals pending.
The opioid crisis has killed hundreds of thousands of Americans, and public health agencies have described it as one of the worst public health crises in modern U.S. history. The Sacklers' role in marketing OxyContin has been extensively documented by the